Kenvue Inc. (NYSE:KVUE) Stock Holdings Reduced by Fmr LLC

Fmr LLC cut its position in shares of Kenvue Inc. (NYSE:KVUE) by 6.5% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 128,972,819 shares of the company’s stock after selling 8,942,674 shares during the period. Fmr LLC owned 6.73% of Kenvue worth $2,753,570,000 as of its most recent SEC filing.

Several other institutional investors have also made changes to their positions in the company. Janus Henderson Group PLC increased its position in Kenvue by 40.6% during the third quarter. Janus Henderson Group PLC now owns 219,576 shares of the company’s stock worth $5,080,000 after buying an additional 63,400 shares during the last quarter. Integrated Wealth Concepts LLC lifted its holdings in Kenvue by 12.8% in the 3rd quarter. Integrated Wealth Concepts LLC now owns 35,022 shares of the company’s stock worth $810,000 after purchasing an additional 3,962 shares during the last quarter. Quarry LP boosted its position in Kenvue by 311.3% during the third quarter. Quarry LP now owns 3,241 shares of the company’s stock worth $75,000 after purchasing an additional 2,453 shares during the period. Quantinno Capital Management LP grew its holdings in Kenvue by 168.4% during the third quarter. Quantinno Capital Management LP now owns 81,314 shares of the company’s stock valued at $1,881,000 after purchasing an additional 51,016 shares during the last quarter. Finally, Voya Financial Advisors Inc. raised its position in shares of Kenvue by 5.8% in the third quarter. Voya Financial Advisors Inc. now owns 21,784 shares of the company’s stock valued at $507,000 after purchasing an additional 1,196 shares during the period. 97.64% of the stock is currently owned by institutional investors and hedge funds.

Kenvue Price Performance

Kenvue stock opened at $22.33 on Friday. The business has a 50 day simple moving average of $22.59 and a 200 day simple moving average of $22.46. Kenvue Inc. has a one year low of $17.67 and a one year high of $24.46. The company has a market capitalization of $42.68 billion, a PE ratio of 42.14, a price-to-earnings-growth ratio of 2.62 and a beta of 1.25. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.00 and a quick ratio of 0.69.

Kenvue (NYSE:KVUE) last posted its earnings results on Thursday, February 6th. The company reported $0.26 earnings per share for the quarter, hitting the consensus estimate of $0.26. Kenvue had a net margin of 6.66% and a return on equity of 20.97%. On average, sell-side analysts forecast that Kenvue Inc. will post 1.14 EPS for the current fiscal year.

Kenvue Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Wednesday, February 26th. Investors of record on Wednesday, February 12th were issued a dividend of $0.205 per share. The ex-dividend date of this dividend was Wednesday, February 12th. This represents a $0.82 dividend on an annualized basis and a yield of 3.67%. Kenvue’s dividend payout ratio is 154.72%.

Analysts Set New Price Targets

A number of research firms recently issued reports on KVUE. Evercore ISI assumed coverage on shares of Kenvue in a research note on Monday, March 24th. They issued an “in-line” rating and a $25.00 target price on the stock. Barclays raised their price target on Kenvue from $21.00 to $23.00 and gave the company an “equal weight” rating in a research report on Thursday, March 27th. Citigroup reduced their price objective on Kenvue from $25.00 to $21.00 and set a “neutral” rating for the company in a research report on Wednesday, January 15th. Canaccord Genuity Group boosted their target price on shares of Kenvue from $24.00 to $29.00 and gave the stock a “buy” rating in a research report on Wednesday, March 5th. Finally, Deutsche Bank Aktiengesellschaft lowered shares of Kenvue from a “buy” rating to a “hold” rating and decreased their price target for the stock from $25.00 to $24.00 in a research report on Thursday, December 12th. One equities research analyst has rated the stock with a sell rating, seven have given a hold rating and five have given a buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Hold” and an average price target of $24.00.

About Kenvue

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.